Association of Health Status Metrics with Clinical Outcomes in Patients with Adult Congenital Heart Disease and Atrial Arrhythmias.
ACHD
SF-36
atrial arrhythmia
congenital heart disease
mEHRA
quality of life
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
20 Oct 2022
20 Oct 2022
Historique:
received:
11
08
2022
revised:
07
10
2022
accepted:
18
10
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
28
10
2022
Statut:
epublish
Résumé
The prognostic value of health status metrics in patients with adult congenital heart disease (ACHD) and atrial arrhythmias is unclear. In this retrospective cohort study of an ongoing national, multicenter registry (PROTECT-AR, NCT03854149), ACHD patients with atrial arrhythmias on apixaban are included. At baseline, health metrics were assessed using the physical component summary (PCS), the mental component summary (MCS) of the Short-Form-36 (SF-36) Health Survey, and the modified European Heart Rhythm Association (mEHRA) score. Patients were divided into groups according to their SF-36 PCS and MCS scores, using the normalized population mean of 50 on the PCS and MCS as a threshold. The primary outcome was the composite of mortality from any cause, major thromboembolic events, major/clinically relevant non-major bleedings, or hospitalizations. Multivariable Cox-regression analyses using clinically relevant parameters (age greater than 60 years, anatomic complexity, ejection fraction of the systemic ventricle, and CHA₂DS₂-VASc and HAS-BLED scores) were performed to examine the association of health metrics with the composite outcome. Over a median follow-up period of 20 months, the composite outcome occurred in 50 of 158 (32%) patients. The risk of the outcome was significantly higher in patients with SF-36 PCS ≤ 50 compared with those with PCS > 50 (adjusted hazard ratio (aHR), 1.98; 95% confidence interval [CI], 1.02−3.84; p = 0.04) after adjusting for possible confounders. The SF-36 MCS ≤ 50 was not associated with the outcome. The mEHRA score was incrementally associated with a higher risk of the composite outcome (aHR = 1.44 per 1 unit increase in score; 95% CI, 1.03−2.00; p = 0.03) in multivariable analysis. In ACHD patients with atrial arrhythmias, the SF-36 PCS ≤ 50 and mEHRA scores predicted an increased risk of adverse events.
Identifiants
pubmed: 36294501
pii: jcm11206181
doi: 10.3390/jcm11206181
pmc: PMC9605619
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Pfizer, through European Thrombosis Investigator-Initiated Research Program (ERISTA)
ID : Reference Number: WI246683
Références
J Am Heart Assoc. 2020 Mar 17;9(6):e014172
pubmed: 32172648
Am J Cardiol. 2004 May 1;93(9):1141-5
pubmed: 15110207
Int J Cardiol. 2013 Oct 30;169(2):139-44
pubmed: 24071387
Int J Cardiol. 2016 Sep 1;218:269-274
pubmed: 27240150
BMJ Open. 2020 Sep 22;10(9):e038012
pubmed: 32963069
Eur Heart J. 2012 Jun;33(11):1386-96
pubmed: 22199119
Heart. 2002 Apr;87(4):356-62
pubmed: 11907011
Diagnostics (Basel). 2022 Feb 11;12(2):
pubmed: 35204557
Int J Cardiol. 2014 Aug 1;175(2):358-62
pubmed: 24973809
Heart. 2002 Jul;88(1):71-5
pubmed: 12067950
J Thromb Haemost. 2005 Apr;3(4):692-4
pubmed: 15842354
Am J Med. 2015 May;128(5):509-18.e2
pubmed: 25534423
Europace. 2014 Jul;16(7):965-72
pubmed: 24534264
Med Care. 1993 Mar;31(3):247-63
pubmed: 8450681
Cardiol Young. 2021 Jan;31(1):97-104
pubmed: 33103640
Int J Cardiol. 2012 Feb 9;154(3):265-9
pubmed: 20926144
Int J Cardiol. 2017 Dec 1;248:152-154
pubmed: 28942870
Korean Circ J. 2015 Jan;45(1):59-66
pubmed: 25653705
Am Heart J. 2019 Dec;218:1-7
pubmed: 31648061
Eur Heart J. 2014 Aug 7;35(30):2001-9
pubmed: 24904027
J Cardiovasc Electrophysiol. 2014 Jan;25(1):23-8
pubmed: 24102986
Heart Rhythm. 2021 May;18(5):793-800
pubmed: 32961334
Eur Heart J. 2021 Feb 1;42(5):373-498
pubmed: 32860505
J Am Heart Assoc. 2018 May 18;7(11):
pubmed: 29776959
Health Qual Life Outcomes. 2007 Sep 07;5:54
pubmed: 17825096
Heart Rhythm. 2014 Jun;11(6):939-45
pubmed: 24632222
Europace. 2018 Nov 1;20(11):1719-1753
pubmed: 29579186
Qual Life Res. 2021 Oct;30(10):2715-2725
pubmed: 34021473
Am Heart J. 2005 Apr;149(4):657-63
pubmed: 15990749
Europace. 2014 Oct;16(10):1417-25
pubmed: 24938627
J Clin Med. 2022 Jul 08;11(14):
pubmed: 35887734
Eur Heart J. 2009 Feb;30(4):497-504
pubmed: 19066211